3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Neoplasms
8
Carcinoma, Medullary
6
Squamous Cell Carcinoma of Head and Neck
4
Head and Neck Neoplasms
3
Thyroid Cancer, Papillary
2
Familial medullary thyroid carcinoma
2
Adenocarcinoma, Follicular
2
Thyroid cancer, medullary
1
Thyroid Diseases
1
Thyroid Carcinoma, Anaplastic
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoid Interstitial Pneumonia
1
Lung Neoplasms
1
Locally Advanced Thyroid Gland Carcinoma
1
Esthesioneuroblastoma, Olfactory
1
Differentiated Thyroid Cancer
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
Thyrotropin Alfa
4
donafenib
2
Injections
2
vandetanib
1
surufatinib
1
pembrolizumab
1
lenvatinib
1
apatinib
1
anlotinib
1
Sorafenib
1
Iodine-131
1
Everolimus
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Differentiated Thyroid Cancer
×
vandetanib
×
Head & Neck
×
Clear all
NCT01876784
2024-07-23
VERIFY
Sanofi
Phase 3
Completed
238 enrolled
12 charts